Sequencing of surgery, immunotherapy impacts outcomes in melanoma
Source: Healio, November 2022
The sequence of surgery and immunotherapy affects outcomes for patients with melanoma, according to a speaker at Chemotherapy Foundation Symposium.
“We have recently had data emerge for neoadjuvant and adjuvant immunotherapy approaches in patients with melanoma,” Sapna P. Patel, MD, director of the uveal melanoma program and program director of the melanoma fellowship at The University of Texas MD Anderson Cancer Center, said during a presentation.
Neoadjuvant setting
“The randomized phase 2 SWOG S1801 trial established that neoadjuvant pembrolizumab [Keytruda, Merck] extended event-free survival compared with adjuvant-only administration of the anti-PD-1 therapy among patients with stage IIIB to stage IV cutaneous, acral mucosal resectable melanoma,” Patel said.